Genetic Technologies and Verizon IndyCar Series Driver Pippa Mann Update BREVAGenplus(R) Marketing Partnership
June 22, 2016 05:30 ET
|
Genetic Technologies
MELBOURNE, AUSTRALIA--(Marketwired - Jun 22, 2016) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"), a molecular diagnostics company specializing in women's health, and provider...
Genetic Technologies Announces Appointment of Senior Medical Director
June 21, 2016 05:30 ET
|
Genetic Technologies
MELBOURNE, AUSTRALIA--(Marketwired - Jun 21, 2016) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"), a molecular diagnostics company specializing in women's health, and provider...
Genetic Technologies and Verizon IndyCar Series Driver Pippa Mann to Ring Nasdaq Stock Market Closing Bell on May 6th, 2016
May 04, 2016 05:30 ET
|
Genetic Technologies
MELBOURNE, AUSTRALIA--(Marketwired - May 4, 2016) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"), a molecular diagnostics company specializing in women's health, and provider...
Opthea Completes Patient Enrolment for OPT-302 Phase 1 Dose Escalation Trial in Patients With Wet AMD
March 30, 2016 18:17 ET
|
Opthea
MELBOURNE, AUSTRALIA--(Marketwired - Mar 30, 2016) -
Phase 1 trial fully enrolled with 20 patients accrued into 4 planned treatment cohorts of 5 patients each
...
Genetic Technologies and IndyCar's Pippa Mann Announce Partnership to Promote BREVAGenplus(R)
February 22, 2016 05:30 ET
|
Genetic Technologies
MELBOURNE, AUSTRALIA--(Marketwired - Feb 22, 2016) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"), a molecular diagnostics company specialising in women's health, is pleased...
Genetic Technologies Announces Publication of Key Scientific Validation Results in Support of BREVAGenplus(R)
December 21, 2015 05:30 ET
|
Genetic Technologies
MELBOURNE, AUSTRALIA--(Marketwired - Dec 21, 2015) - Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company") announced today the publication of a new...
ARMO BioSciences Presents Positive Phase 1 Trial Results of AM0010 at Upcoming Medical Conferences
October 30, 2015 05:30 ET
|
ARMO BioSciences
REDWOOD CITY, CA--(Marketwired - Oct 30, 2015) - ARMO BioSciences, Inc., a leading developer of immuno-oncology therapeutics, today announced that positive results from an ongoing Phase 1 clinical...
Open Monoclonal Technology and ARMO BioSciences Announce Anti-PD1 Antibody and OmniAb(TM) Platform License Agreement
October 16, 2015 05:30 ET
|
ARMO Biosciences
REDWOOD CITY, CA and PALO ALTO, CA--(Marketwired - Oct 16, 2015) - ARMO BioSciences, Inc. (ARMO), a leading developer of immuno-oncology therapeutics and Open Monoclonal Technology, Inc. (OMT),...
Genetic Technologies Granted Key Patents by US Patent Office for BREVAGenplus(R)
August 06, 2015 05:30 ET
|
Genetic Technologies
MELBOURNE, AUSTRALIA--(Marketwired - Aug 6, 2015) - Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"), is pleased to announce the issuance of US...
Genetic Technologies Announces Scientific Validation, Clinical Trial and Peer Review Publication Initiatives
July 14, 2015 05:30 ET
|
Genetic Technologies
MELBOURNE, AUSTRALIA--(Marketwired - Jul 14, 2015) - Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"), is pleased to announce that underpinned by a...